Compare Gilead Sciences, Inc. (GILD) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs IQIYI Inc - ADR — how do they compare? Gilead Sciences, Inc. trades at $133.5 (market cap $163.51B), while IQIYI Inc - ADR trades at $1.23 (market cap $1.15B). The key difference: Gilead Sciences, Inc. is far larger — about 142.2× IQIYI Inc - ADR's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while IQIYI Inc - ADR pays none. Which is the better fit depends on your goals.
| GILD | IQ | |
|---|---|---|
Market Cap | $163.51B | $1.15B |
Sector | Health | Media |
52-Week High | $155.80 | $2.79 |
52-Week Low | $108.22 | $0.96 |
Enterprise Value | $178.05B | $2.71B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
IQ (iQIYI) trades at $1.16, up 2.65% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company reported a net loss of $206.31 million in 2025, with revenue declining to $27.29 billion, though it beat EPS expectations in two of the last three quarters. Recent news highlights AI platform growth and leadership changes as potential turnaround catalysts.
The outlook is mixed: analyst consensus leans buy (50%) with price predictions citing upside potential, but profitability challenges and revenue declines pose risks. Investment opportunity hinges on AI-driven content innovation offsetting competitive pressures in China's streaming market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
